Galsulfase: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Galsulfase. Educational only — not medical advice.
Labeled uses
NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome). NAGLAZYME has been shown to improve walking and stair-climbing capacity.
Source: FDA labeling via NIH DailyMed (set 59341250…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.